# Nancy U. Lin

Source: https://onco.cc/people/nancy-lin/  
OnCo record `nancy-lin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nancy Lin is the leading authority on brain metastases from breast cancer, including the HER2CLIMB tucatinib data in patients with active brain disease.

## Summary

Nancy U. Lin is Director of the Metastatic Breast Cancer Program and Associate Chief of the Division of Breast Oncology at Dana-Farber Brigham Cancer Center. She is the leading authority on brain metastases from breast cancer, known for the HER2CLIMB analyses of tucatinib in patients with active brain disease and for defining the RANO-BM central nervous system response criteria used across trials. Her selected paper reports intracranial efficacy of tucatinib plus trastuzumab and capecitabine in previously treated HER2-positive breast cancer with brain metastases. She directs the metastatic breast cancer programme and continues work on CNS pharmacology in HER2-positive disease.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Metastatic Breast Cancer Program; Associate Chief, Division of Breast Oncology
- Specialisms: Breast cancer brain metastases; HER2-positive breast cancer; CNS pharmacology

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Nancy_Lin
- Dana-Farber profile: https://www.dana-farber.org/find-a-doctor/nancy-u-lin
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Lin%20NU%5BAuthor%5D

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Tucatinib](https://onco.cc/drugs/tucatinib/)
- institutions: [Breast Cancer Research Foundation](https://onco.cc/institutions/bcrf/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- trials: [HER2CLIMB](https://onco.cc/trials/her2climb/)
- key papers: [Prevalence and mutational determinants of high tumor mutation burden in breast cancer](https://onco.cc/key-papers/paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020/), [Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases](https://onco.cc/key-papers/paper-lin-tnbc-cns-metastases-dfci-cancer-2008/), [Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- ideas: [Trials that include, and report, brain metastases in triple-negative breast cancer](https://onco.cc/ideas/idea-tnbc-brain-metastasis-trials/)

---
JSON: https://onco.cc/api/v1/entities/nancy-lin.json